Chinese  ||| S:0 E:8 ||| JJ
subgroup  ||| S:8 E:17 ||| JJ
analysis  ||| S:17 E:26 ||| NN
of  ||| S:26 E:29 ||| IN
the  ||| S:29 E:33 ||| DT
global  ||| S:33 E:40 ||| JJ
anticoagulant  ||| S:40 E:54 ||| JJ
registry  ||| S:54 E:63 ||| NN
in  ||| S:63 E:66 ||| IN
the  ||| S:66 E:70 ||| DT
FIELD  ||| S:70 E:76 ||| NNP
( ||| S:76 E:77 ||| -LRB-
GARFIELD ||| S:77 E:85 ||| NNP
)  ||| S:85 E:87 ||| -RRB-
registry  ||| S:87 E:96 ||| NN
in  ||| S:96 E:99 ||| IN
the  ||| S:99 E:103 ||| DT
patients  ||| S:103 E:112 ||| NNS
with  ||| S:112 E:117 ||| IN
non-valvular  ||| S:117 E:130 ||| JJ
atrial  ||| S:130 E:137 ||| JJ
fibrillation  ||| S:137 E:150 ||| NN
To  ||| S:150 E:153 ||| TO
describe  ||| S:153 E:162 ||| VB
the  ||| S:162 E:166 ||| DT
baseline  ||| S:166 E:175 ||| NN
characteristics  ||| S:175 E:191 ||| NNS
and  ||| S:191 E:195 ||| CC
antithrombotic  ||| S:195 E:210 ||| JJ
treatment  ||| S:210 E:220 ||| NN
of  ||| S:220 E:223 ||| IN
patients  ||| S:223 E:232 ||| NNS
with  ||| S:232 E:237 ||| IN
non-valvular  ||| S:237 E:250 ||| JJ
atrial  ||| S:250 E:257 ||| JJ
fibrillation  ||| S:257 E:270 ||| NN
in  ||| S:270 E:273 ||| IN
the  ||| S:273 E:277 ||| DT
Chinese  ||| S:277 E:285 ||| JJ
subgroup  ||| S:285 E:294 ||| NN
of  ||| S:294 E:297 ||| IN
GRAFIELD ||| S:297 E:305 ||| NNP
.  ||| S:305 E:307 ||| .
GARFIELD  ||| S:307 E:316 ||| NNP
is  ||| S:316 E:319 ||| VBZ
an  ||| S:319 E:322 ||| DT
observational  ||| S:322 E:336 ||| JJ
registry  ||| S:336 E:345 ||| JJ
study  ||| S:345 E:351 ||| NN
for  ||| S:351 E:355 ||| IN
patients  ||| S:355 E:364 ||| NNS
with  ||| S:364 E:369 ||| IN
newly  ||| S:369 E:375 ||| RB
diagnosed  ||| S:375 E:385 ||| VBN
non-valvular  ||| S:385 E:398 ||| JJ
atrial  ||| S:398 E:405 ||| JJ
fibrillation ||| S:405 E:417 ||| NN
.  ||| S:417 E:419 ||| .
A  ||| S:419 E:421 ||| DT
total  ||| S:421 E:427 ||| NN
of  ||| S:427 E:430 ||| IN
805  ||| S:430 E:434 ||| CD
adult  ||| S:434 E:440 ||| NN
(  ||| S:440 E:442 ||| -LRB-
≥18  ||| S:442 E:446 ||| CD
years  ||| S:446 E:452 ||| NNS
old ||| S:452 E:455 ||| JJ
)  ||| S:455 E:457 ||| -RRB-
patients  ||| S:457 E:466 ||| NNS
( ||| S:466 E:467 ||| -LRB-
mean  ||| S:467 E:472 ||| JJ
age ||| S:472 E:475 ||| NN
:  ||| S:475 E:477 ||| :
( ||| S:477 E:478 ||| -LRB-
66.6  ||| S:478 E:483 ||| CD
±  ||| S:483 E:485 ||| CD
11.4 ||| S:485 E:489 ||| CD
)  ||| S:489 E:491 ||| -RRB-
years  ||| S:491 E:497 ||| NNS
old ||| S:497 E:500 ||| JJ
,  ||| S:500 E:502 ||| ,
39.4 ||| S:502 E:506 ||| CD
%  ||| S:506 E:508 ||| NN
female  ||| S:508 E:515 ||| NN
( ||| S:515 E:516 ||| -LRB-
n  ||| S:516 E:518 ||| CD
=  ||| S:518 E:520 ||| SYM
317 ||| S:520 E:523 ||| CD
) ||| S:523 E:524 ||| -RRB-
)  ||| S:524 E:526 ||| -RRB-
diagnosed  ||| S:526 E:536 ||| VBD
with  ||| S:536 E:541 ||| IN
non-valvular  ||| S:541 E:554 ||| JJ
atrial  ||| S:554 E:561 ||| JJ
fibrillation  ||| S:561 E:574 ||| NN
within  ||| S:574 E:581 ||| IN
the  ||| S:581 E:585 ||| DT
previous  ||| S:585 E:594 ||| JJ
6  ||| S:594 E:596 ||| CD
weeks  ||| S:596 E:602 ||| NNS
were  ||| S:602 E:607 ||| VBD
recruited  ||| S:607 E:617 ||| VBN
between  ||| S:617 E:625 ||| IN
December  ||| S:625 E:634 ||| NNP
2009  ||| S:634 E:639 ||| CD
and  ||| S:639 E:643 ||| CC
October  ||| S:643 E:651 ||| NNP
2011  ||| S:651 E:656 ||| CD
at  ||| S:656 E:659 ||| IN
29  ||| S:659 E:662 ||| CD
hospitals  ||| S:662 E:672 ||| NNS
from  ||| S:672 E:677 ||| IN
China ||| S:677 E:682 ||| NNP
.  ||| S:682 E:684 ||| .
Baseline  ||| S:684 E:693 ||| JJ
data  ||| S:693 E:698 ||| NNS
included  ||| S:698 E:707 ||| VBD
demographics ||| S:707 E:719 ||| NNS
,  ||| S:719 E:721 ||| ,
medical  ||| S:721 E:729 ||| JJ
history ||| S:729 E:736 ||| NN
,  ||| S:736 E:738 ||| ,
nature  ||| S:738 E:745 ||| NN
of  ||| S:745 E:748 ||| IN
atrial  ||| S:748 E:755 ||| JJ
fibrillation ||| S:755 E:767 ||| NN
,  ||| S:767 E:769 ||| ,
CHA ||| S:769 E:772 ||| NNP
( ||| S:772 E:773 ||| -LRB-
2 ||| S:773 E:774 ||| LS
) ||| S:774 E:775 ||| -RRB-
DS ||| S:775 E:777 ||| NNP
( ||| S:777 E:778 ||| -LRB-
2 ||| S:778 E:779 ||| LS
)  ||| S:779 E:781 ||| -RRB-
score ||| S:781 E:786 ||| NN
,  ||| S:786 E:788 ||| ,
CHA ||| S:788 E:791 ||| NNP
( ||| S:791 E:792 ||| -LRB-
2 ||| S:792 E:793 ||| LS
) ||| S:793 E:794 ||| -RRB-
DS ||| S:794 E:796 ||| NNP
( ||| S:796 E:797 ||| -LRB-
2 ||| S:797 E:798 ||| LS
) ||| S:798 E:799 ||| -RRB-
-VASc  ||| S:799 E:805 ||| JJ
score ||| S:805 E:810 ||| NN
,  ||| S:810 E:812 ||| ,
and  ||| S:812 E:816 ||| CC
treatment  ||| S:816 E:826 ||| NN
at  ||| S:826 E:829 ||| IN
the  ||| S:829 E:833 ||| DT
time  ||| S:833 E:838 ||| NN
of  ||| S:838 E:841 ||| IN
diagnosis ||| S:841 E:850 ||| NN
.  ||| S:850 E:852 ||| .
There  ||| S:852 E:858 ||| EX
were  ||| S:858 E:863 ||| VBD
216  ||| S:863 E:867 ||| CD
patients  ||| S:867 E:876 ||| NNS
( ||| S:876 E:877 ||| -LRB-
26.8 ||| S:877 E:881 ||| CD
% ||| S:881 E:882 ||| NN
)  ||| S:882 E:884 ||| -RRB-
with  ||| S:884 E:889 ||| IN
age  ||| S:889 E:893 ||| NN
above  ||| S:893 E:899 ||| IN
75  ||| S:899 E:902 ||| CD
years  ||| S:902 E:908 ||| NNS
old ||| S:908 E:911 ||| JJ
,  ||| S:911 E:913 ||| ,
116  ||| S:913 E:917 ||| CD
patients  ||| S:917 E:926 ||| NNS
( ||| S:926 E:927 ||| -LRB-
14.4 ||| S:927 E:931 ||| CD
% ||| S:931 E:932 ||| NN
)  ||| S:932 E:934 ||| -RRB-
had  ||| S:934 E:938 ||| VBD
history  ||| S:938 E:946 ||| NN
of  ||| S:946 E:949 ||| IN
stroke  ||| S:949 E:956 ||| NN
or  ||| S:956 E:959 ||| CC
TIA ||| S:959 E:962 ||| NNP
,  ||| S:962 E:964 ||| ,
261  ||| S:964 E:968 ||| CD
patients  ||| S:968 E:977 ||| NNS
( ||| S:977 E:978 ||| -LRB-
32.4 ||| S:978 E:982 ||| CD
% ||| S:982 E:983 ||| NN
)  ||| S:983 E:985 ||| -RRB-
had  ||| S:985 E:989 ||| VBD
coronary  ||| S:989 E:998 ||| JJ
artery  ||| S:998 E:1005 ||| NN
disease ||| S:1005 E:1012 ||| NN
.  ||| S:1012 E:1014 ||| .
Mean  ||| S:1014 E:1019 ||| NNP
CHADS ||| S:1019 E:1024 ||| NNP
( ||| S:1024 E:1025 ||| -LRB-
2 ||| S:1025 E:1026 ||| LS
)  ||| S:1026 E:1028 ||| -RRB-
score  ||| S:1028 E:1034 ||| NN
was  ||| S:1034 E:1038 ||| VBD
1.7  ||| S:1038 E:1042 ||| CD
±  ||| S:1042 E:1044 ||| CD
1.1 ||| S:1044 E:1047 ||| CD
,  ||| S:1047 E:1049 ||| ,
and  ||| S:1049 E:1053 ||| CC
391  ||| S:1053 E:1057 ||| CD
patients  ||| S:1057 E:1066 ||| NNS
( ||| S:1066 E:1067 ||| -LRB-
48.5 ||| S:1067 E:1071 ||| NNP
% ||| S:1071 E:1072 ||| NN
)  ||| S:1072 E:1074 ||| -RRB-
had  ||| S:1074 E:1078 ||| VBD
a  ||| S:1078 E:1080 ||| DT
CHADS ||| S:1080 E:1085 ||| NNP
( ||| S:1085 E:1086 ||| -LRB-
2 ||| S:1086 E:1087 ||| LS
)  ||| S:1087 E:1089 ||| -RRB-
score  ||| S:1089 E:1095 ||| VBP
≥  ||| S:1095 E:1097 ||| CD
2 ||| S:1097 E:1098 ||| CD
.  ||| S:1098 E:1100 ||| .
Mean  ||| S:1100 E:1105 ||| NNP
CHA ||| S:1105 E:1108 ||| NNP
( ||| S:1108 E:1109 ||| -LRB-
2 ||| S:1109 E:1110 ||| LS
) ||| S:1110 E:1111 ||| -RRB-
DS ||| S:1111 E:1113 ||| NNP
( ||| S:1113 E:1114 ||| -LRB-
2 ||| S:1114 E:1115 ||| LS
) ||| S:1115 E:1116 ||| -RRB-
-VASc  ||| S:1116 E:1122 ||| JJ
score  ||| S:1122 E:1128 ||| NN
was  ||| S:1128 E:1132 ||| VBD
2.9  ||| S:1132 E:1136 ||| CD
±  ||| S:1136 E:1138 ||| CD
1.7 ||| S:1138 E:1141 ||| CD
,  ||| S:1141 E:1143 ||| ,
and  ||| S:1143 E:1147 ||| CC
630  ||| S:1147 E:1151 ||| CD
patients  ||| S:1151 E:1160 ||| NNS
( ||| S:1160 E:1161 ||| -LRB-
78.3 ||| S:1161 E:1165 ||| NNP
% ||| S:1165 E:1166 ||| NN
)  ||| S:1166 E:1168 ||| -RRB-
had  ||| S:1168 E:1172 ||| VBD
a  ||| S:1172 E:1174 ||| DT
CHA ||| S:1174 E:1177 ||| NNP
( ||| S:1177 E:1178 ||| -LRB-
2 ||| S:1178 E:1179 ||| LS
) ||| S:1179 E:1180 ||| -RRB-
DS ||| S:1180 E:1182 ||| NNP
( ||| S:1182 E:1183 ||| -LRB-
2 ||| S:1183 E:1184 ||| LS
) ||| S:1184 E:1185 ||| -RRB-
-VASc  ||| S:1185 E:1191 ||| JJ
score  ||| S:1191 E:1197 ||| NN
≥  ||| S:1197 E:1199 ||| CD
2.Overall ||| S:1199 E:1208 ||| CD
,  ||| S:1208 E:1210 ||| ,
159  ||| S:1210 E:1214 ||| CD
patients  ||| S:1214 E:1223 ||| NNS
( ||| S:1223 E:1224 ||| -LRB-
19.8 ||| S:1224 E:1228 ||| CD
% ||| S:1228 E:1229 ||| NN
)  ||| S:1229 E:1231 ||| -RRB-
received  ||| S:1231 E:1240 ||| VBD
no  ||| S:1240 E:1243 ||| DT
anticoagulant  ||| S:1243 E:1257 ||| JJ
treatment ||| S:1257 E:1266 ||| NN
,  ||| S:1266 E:1268 ||| ,
51.6 ||| S:1268 E:1272 ||| CD
%  ||| S:1272 E:1274 ||| NN
( ||| S:1274 E:1275 ||| -LRB-
n  ||| S:1275 E:1277 ||| CD
=  ||| S:1277 E:1279 ||| SYM
415 ||| S:1279 E:1282 ||| CD
)  ||| S:1282 E:1284 ||| -RRB-
patients  ||| S:1284 E:1293 ||| NNS
received  ||| S:1293 E:1302 ||| VBD
aspirin  ||| S:1302 E:1310 ||| JJ
and  ||| S:1310 E:1314 ||| CC
only  ||| S:1314 E:1319 ||| RB
28.7 ||| S:1319 E:1323 ||| CD
%  ||| S:1323 E:1325 ||| NN
( ||| S:1325 E:1326 ||| -LRB-
n  ||| S:1326 E:1328 ||| CD
=  ||| S:1328 E:1330 ||| SYM
231 ||| S:1330 E:1333 ||| CD
)  ||| S:1333 E:1335 ||| -RRB-
patients  ||| S:1335 E:1344 ||| NNS
received  ||| S:1344 E:1353 ||| VBD
either  ||| S:1353 E:1360 ||| DT
warfarin  ||| S:1360 E:1369 ||| NN
( ||| S:1369 E:1370 ||| -LRB-
n  ||| S:1370 E:1372 ||| CD
=  ||| S:1372 E:1374 ||| SYM
179 ||| S:1374 E:1377 ||| CD
,  ||| S:1377 E:1379 ||| ,
22.2 ||| S:1379 E:1383 ||| CD
% ||| S:1383 E:1384 ||| NN
)  ||| S:1384 E:1386 ||| -RRB-
or  ||| S:1386 E:1389 ||| CC
new  ||| S:1389 E:1393 ||| JJ
oral  ||| S:1393 E:1398 ||| JJ
anticoagulants  ||| S:1398 E:1413 ||| NNS
( ||| S:1413 E:1414 ||| -LRB-
NOAC ||| S:1414 E:1418 ||| NNP
)  ||| S:1418 E:1420 ||| -RRB-
( ||| S:1420 E:1421 ||| -LRB-
n  ||| S:1421 E:1423 ||| CD
=  ||| S:1423 E:1425 ||| SYM
52 ||| S:1425 E:1427 ||| CD
,  ||| S:1427 E:1429 ||| ,
6.5 ||| S:1429 E:1432 ||| CD
% ||| S:1432 E:1433 ||| NN
) ||| S:1433 E:1434 ||| -RRB-
.  ||| S:1434 E:1436 ||| .
Among  ||| S:1436 E:1442 ||| IN
patients  ||| S:1442 E:1451 ||| NNS
with  ||| S:1451 E:1456 ||| IN
CHADS2  ||| S:1456 E:1463 ||| CD
score  ||| S:1463 E:1469 ||| CD
≥  ||| S:1469 E:1471 ||| CD
2  ||| S:1471 E:1473 ||| CD
( ||| S:1473 E:1474 ||| -LRB-
n  ||| S:1474 E:1476 ||| CD
=  ||| S:1476 E:1478 ||| SYM
391 ||| S:1478 E:1481 ||| CD
) ||| S:1481 E:1482 ||| -RRB-
,  ||| S:1482 E:1484 ||| ,
68.3 ||| S:1484 E:1488 ||| CD
%  ||| S:1488 E:1490 ||| NN
patients  ||| S:1490 E:1499 ||| NNS
( ||| S:1499 E:1500 ||| -LRB-
n  ||| S:1500 E:1502 ||| CD
=  ||| S:1502 E:1504 ||| SYM
267 ||| S:1504 E:1507 ||| CD
)  ||| S:1507 E:1509 ||| -RRB-
did  ||| S:1509 E:1513 ||| VBD
not  ||| S:1513 E:1517 ||| RB
receive  ||| S:1517 E:1525 ||| VB
anticoagulant  ||| S:1525 E:1539 ||| JJ
therapy ||| S:1539 E:1546 ||| NN
.  ||| S:1546 E:1548 ||| .
Among  ||| S:1548 E:1554 ||| IN
patients  ||| S:1554 E:1563 ||| NNS
with  ||| S:1563 E:1568 ||| IN
CHA ||| S:1568 E:1571 ||| NNP
( ||| S:1571 E:1572 ||| -LRB-
2 ||| S:1572 E:1573 ||| LS
) ||| S:1573 E:1574 ||| -RRB-
DS ||| S:1574 E:1576 ||| NNP
( ||| S:1576 E:1577 ||| -LRB-
2 ||| S:1577 E:1578 ||| LS
) ||| S:1578 E:1579 ||| -RRB-
-VASc  ||| S:1579 E:1585 ||| JJ
≥  ||| S:1585 E:1587 ||| CD
2  ||| S:1587 E:1589 ||| CD
( ||| S:1589 E:1590 ||| -LRB-
n  ||| S:1590 E:1592 ||| CD
=  ||| S:1592 E:1594 ||| SYM
630 ||| S:1594 E:1597 ||| CD
) ||| S:1597 E:1598 ||| -RRB-
,  ||| S:1598 E:1600 ||| ,
71.7 ||| S:1600 E:1604 ||| CD
%  ||| S:1604 E:1606 ||| NN
( ||| S:1606 E:1607 ||| -LRB-
n  ||| S:1607 E:1609 ||| CD
=  ||| S:1609 E:1611 ||| SYM
452 ||| S:1611 E:1614 ||| CD
)  ||| S:1614 E:1616 ||| -RRB-
did  ||| S:1616 E:1620 ||| VBD
not  ||| S:1620 E:1624 ||| RB
receive  ||| S:1624 E:1632 ||| VB
anticoagulant  ||| S:1632 E:1646 ||| JJ
therapy ||| S:1646 E:1653 ||| NN
.  ||| S:1653 E:1655 ||| .
For  ||| S:1655 E:1659 ||| IN
the  ||| S:1659 E:1663 ||| DT
patients  ||| S:1663 E:1672 ||| NNS
with  ||| S:1672 E:1677 ||| IN
very  ||| S:1677 E:1682 ||| RB
high  ||| S:1682 E:1687 ||| JJ
risk  ||| S:1687 E:1692 ||| NN
of  ||| S:1692 E:1695 ||| IN
stroke ||| S:1695 E:1701 ||| NN
,  ||| S:1701 E:1703 ||| ,
i.e.  ||| S:1703 E:1708 ||| FW
CHA ||| S:1708 E:1711 ||| FW
( ||| S:1711 E:1712 ||| -LRB-
2 ||| S:1712 E:1713 ||| LS
) ||| S:1713 E:1714 ||| -RRB-
DS ||| S:1714 E:1716 ||| NNP
( ||| S:1716 E:1717 ||| -LRB-
2 ||| S:1717 E:1718 ||| LS
) ||| S:1718 E:1719 ||| -RRB-
-VASc  ||| S:1719 E:1725 ||| JJ
≥  ||| S:1725 E:1727 ||| CD
6 ||| S:1727 E:1728 ||| CD
,  ||| S:1728 E:1730 ||| ,
the  ||| S:1730 E:1734 ||| DT
proportion  ||| S:1734 E:1745 ||| NN
of  ||| S:1745 E:1748 ||| IN
the  ||| S:1748 E:1752 ||| DT
patients  ||| S:1752 E:1761 ||| NNS
received  ||| S:1761 E:1770 ||| VBD
NOAC  ||| S:1770 E:1775 ||| NNP
and  ||| S:1775 E:1779 ||| CC
warfarin  ||| S:1779 E:1788 ||| NNS
were  ||| S:1788 E:1793 ||| VBD
identical  ||| S:1793 E:1803 ||| JJ
( ||| S:1803 E:1804 ||| -LRB-
14.9 ||| S:1804 E:1808 ||| CD
% ||| S:1808 E:1809 ||| NN
,  ||| S:1809 E:1811 ||| ,
7 ||| S:1811 E:1812 ||| CD
/ ||| S:1812 E:1813 ||| CD
47 ||| S:1813 E:1815 ||| CD
) ||| S:1815 E:1816 ||| -RRB-
.  ||| S:1816 E:1818 ||| .
This  ||| S:1818 E:1823 ||| DT
contemporary  ||| S:1823 E:1836 ||| JJ
observational  ||| S:1836 E:1850 ||| JJ
registry  ||| S:1850 E:1859 ||| JJ
study  ||| S:1859 E:1865 ||| NN
shows  ||| S:1865 E:1871 ||| NNS
that  ||| S:1871 E:1876 ||| IN
the  ||| S:1876 E:1880 ||| DT
anticoagulant  ||| S:1880 E:1894 ||| JJ
therapy  ||| S:1894 E:1902 ||| NN
is  ||| S:1902 E:1905 ||| VBZ
somehow  ||| S:1905 E:1913 ||| RB
improved  ||| S:1913 E:1922 ||| VBN
but  ||| S:1922 E:1926 ||| CC
still  ||| S:1926 E:1932 ||| RB
underused  ||| S:1932 E:1942 ||| VBN
in  ||| S:1942 E:1945 ||| IN
Chinese  ||| S:1945 E:1953 ||| NNP
NVAF  ||| S:1953 E:1958 ||| NNP
patients ||| S:1958 E:1966 ||| NNS
.  ||| S:1966 E:1968 ||| .
Stroke  ||| S:1968 E:1975 ||| JJ
prevention  ||| S:1975 E:1986 ||| NN
according  ||| S:1986 E:1996 ||| VBG
to  ||| S:1996 E:1999 ||| TO
risk  ||| S:1999 E:2004 ||| VB
scores  ||| S:2004 E:2011 ||| NNS
and  ||| S:2011 E:2015 ||| CC
current  ||| S:2015 E:2023 ||| JJ
guidelines  ||| S:2023 E:2034 ||| NNS
in  ||| S:2034 E:2037 ||| IN
these  ||| S:2037 E:2043 ||| DT
patients  ||| S:2043 E:2052 ||| NNS
remains  ||| S:2052 E:2060 ||| VBZ
an  ||| S:2060 E:2063 ||| DT
important  ||| S:2063 E:2073 ||| JJ
task  ||| S:2073 E:2078 ||| NN
in  ||| S:2078 E:2081 ||| IN
China ||| S:2081 E:2086 ||| NNP
.  ||| S:2086 E:2088 ||| .
